3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
54
Lymphoma, Mantle-Cell
31
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Non-Hodgkin
14
Lymphoma
11
Leukemia, B-Cell
7
Lymphoma, Follicular
5
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma, B-Cell
5
Leukemia
5
Waldenstrom Macroglobulinemia
4
Recurrence
2
Multiple Myeloma
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Prolymphocytic
2
Pyloric Stenosis, Hypertrophic
1
Part1: Advanced B-cell Malignancies
1
Neuritis
1
Neoplasms
1
Neoplasm, Residual
1
Leukemia, Hairy Cell
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Hematologic Diseases
1
Heart Failure
1
Glioblastoma
1
DLBCL
1
Chromosome 17 deletion
1
Interventions
Brentuximab Vedotin
21
Cyclophosphamide
17
Rituximab
11
fludarabine
9
Mycophenolic Acid
9
pirtobrutinib
7
dacetuzumab
7
Busulfan
7
fludarabine phosphate
6
Tacrolimus
6
Melphalan
6
Whole-Body Irradiation
5
Doxorubicin
5
Vincristine
4
Prednisone
4
Mesna
4
Etoposide
4
Bone Marrow Transplantation
4
Bendamustine Hydrochloride
4
ibrutinib
3
Thiotepa
3
Sirolimus
3
Cyclosporine
3
Bortezomib
3
ponatinib
2
Vorinostat
2
Stem Cell Transplantation
2
Rifampin
2
Platelet Transfusion
2
Peripheral Blood Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
acalabrutinib
×
Lymphoid
×
Clear all
NCT04662255
2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3
Active not recruiting
500 enrolled